Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.32 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.31 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623394 | 0.81 | SLC13A5 (0.33) | SLC13A5SLC13A2SLC13A3 | |
| SCHEMBL6760098 | 0.77 | SLC13A5 (0.30) | SLC13A5 | |
| SCHEMBL2207722 | 0.69 | STING1 (0.33) | — | |
| SCHEMBL6762127 | 0.66 | — | — | |
| SCHEMBL2798702 | 0.63 | SLC13A5 (0.42) | SLC13A5SLC13A2SLC13A3 | |
| SCHEMBL2798693 | 0.63 | SLC13A5 (0.42) | SLC13A5SLC13A2SLC13A3 | |
| SCHEMBL6757707 | 0.62 | ACSS2 (0.33) | — | |
| SCHEMBL6762174 | 0.61 | ACSS2 (0.34) | SLC13A5 | |
| SCHEMBL7056948 | 0.54 | CYP2C19 (0.57) | — | |
| SCHEMBL687446 | 0.54 | CYP2C19 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723853-B2 | ANTICANCER AGENTS | UNIVERSITY OF PITTSBURGH | 2004-04-20 | — | — | US | disclosed |
| US-20030073840-A1 | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073840-A1 | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins | FOLR1, POR, FOLR2 | SLC13A5 380/4885SLC13A2 718/4885SLC13A3 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.